2. Academic Validation
  3. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture

Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture

  • Cell Rep. 2021 May 18;35(7):109133. doi: 10.1016/j.celrep.2021.109133.
Khushboo Bafna 1,  Kris White 2,  Balasubramanian Harish 3,  Romel Rosales 2,  Theresa A Ramelot 1,  Thomas B Acton 1,  Elena Moreno 2,  Thomas Kehrer 2,  Lisa Miorin 2,  Catherine A Royer 3,  Adolfo García-Sastre 4,  Robert M Krug 5,  Gaetano T Montelione 6
Affiliations

Affiliations

  • 1 Department of Chemistry and Chemical Biology, and Center for Biotechnology and Interdisciplinary Sciences, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
  • 2 Department of Microbiology, and Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • 3 Department of Biology, and Center for Biotechnology and Interdisciplinary Sciences, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
  • 4 Department of Microbiology, and Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: adolfo.garcia-sastre@mssm.edu.
  • 5 Department of Molecular Biosciences, John Ring LaMontagne Center for Infectious Disease, Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX 78712, USA. Electronic address: rkrug@austin.utexas.edu.
  • 6 Department of Chemistry and Chemical Biology, and Center for Biotechnology and Interdisciplinary Sciences, Rensselaer Polytechnic Institute, Troy, NY 12180, USA. Electronic address: monteg3@rpi.edu.
PMID: 33984267 DOI: 10.1016/j.celrep.2021.109133
Abstract

Effective control of COVID-19 requires antivirals directed against SARS-CoV-2. We assessed 10 hepatitis C virus (HCV) protease-inhibitor drugs as potential SARS-CoV-2 antivirals. There is a striking structural similarity of the substrate binding clefts of SARS-CoV-2 main protease (Mpro) and HCV NS3/4A protease. Virtual docking experiments show that these HCV drugs can potentially bind into the Mpro substrate-binding cleft. We show that seven HCV drugs inhibit both SARS-CoV-2 Mpro protease activity and SARS-CoV-2 virus replication in Vero and/or human cells. However, their Mpro inhibiting activities did not correlate with their Antiviral activities. This conundrum is resolved by demonstrating that four HCV Protease Inhibitor drugs, simeprevir, vaniprevir, paritaprevir, and grazoprevir inhibit the SARS CoV-2 papain-like protease (PLpro). HCV drugs that inhibit PLpro synergize with the viral polymerase inhibitor remdesivir to inhibit virus replication, increasing remdesivir's Antiviral activity as much as 10-fold, while those that only inhibit Mpro do not synergize with remdesivir.

Keywords

COVID-19; HCV protease inhibitors; SARS-CoV-2 3CL/M(pro) protease; SARS-CoV-2 PL protease; SARS-CoV-2 virus replication; antivirals; molecular docking; remdesivir; synergism.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z